Multiple chemotherapeutic agents, such as Bortezomib, Melphalan, and Doxorubicin, have been shown to upregulate DNAM-1 and NKG2D ligands to enhance the lysis of multiple myeloma cells by NK cells [107, 108]. Here, KLRK1 is linked to plasma cell myeloma.